Eurocine Vaccines said that results from a study of its Immunose Flu intranasal flu vaccine in adults aged 50-70 showed no serious adverse events and only minimal experiences of discomfort.
The study, which took place during the 2017/18 flu season, enrolled 298 subjects at 5 locations in Sweden. The subjects, who had a mean age of 63, were divided into treatment groups that compared Immunose Flu, an intranasal influenza antigen, an intramuscular injection of flu vaccine, and placebo.
Eurocine Vaccines VP R&D and Chief Scientific Officer Anna-Karin Maltais commented, “I am very happy that we have once again confirmed good safety, this time in older adults, a population in need of better influenza vaccines. Now we look forward to the immunological results, which are expected in October.”
CEO Hans Arwidsson said, “The data put us exactly where we want to be for our further development and in our hunt for the next vaccine project.”
Read the Eurocine Vaccines press release.
